A Novel Low-grade Nasopharyngeal Adenocarcinoma Characterized by a GOLGB1-BRAF Fusion Gene
Overview
Oncology
Authors
Affiliations
Nasopharyngeal adenocarcinoma is a rare malignancy that is classified into conventional/surface- and salivary-types. Herein we report the case of a 52-year-old male who presented with a right nasopharyngeal mass and right-sided hearing loss. Diagnostic imaging revealed a circumscribed 1.7 cm mass centred in the right antero-lateral aspect of the nasopharynx. A biopsy showed a gland-forming neoplasm that was in continuity with the surface epithelium. The tumor exhibited a nested to micro-papillary architecture, with mild cytologic atypia. Immunohistochemistry demonstrated diffuse staining for CK7, SOX10, and p16; the abluminal layer was highlighted by CK5 and p63, while the luminal cells expressed CD117. The tumor was not amenable to subclassification and was diagnosed as a low-grade nasopharyngeal adenocarcinoma, not otherwise specified (NOS). Subsequent RNA sequencing was performed which identified a novel GOLGB1-BRAF fusion product. Based on its unique morphology and molecular findings, this is presumed to represent a novel subtype of nasopharyngeal adenocarcinoma. In addition to being of diagnostic relevance, this fusion may ultimately represent a potential therapeutic target.
Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib.
Kato H, Kano S, Yasui Y, Nojiri Y, Yoshimitsu M, Nakamura M Case Rep Oncol. 2023; 16(1):1007-1012.
PMID: 37900828 PMC: 10601785. DOI: 10.1159/000533822.
Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.
Loo S, Yates M, Yang S, Oesterreich S, Lee A, Wang X Genes Chromosomes Cancer. 2022; 61(5):261-273.
PMID: 35106856 PMC: 8930468. DOI: 10.1002/gcc.23029.